


PRODUCT: PF-04691502

ALTERNATE NAME: 2-amino-8-((1*r*,4*r*)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxy-pyridin-3-yl)-4-methylpyrido[2,3-*d*]pyrimidin-7(8*H*)-one

CATALOG #: 2289-5, 25

AMOUNT: 5 mg, 25 mg

STRUCTURE:



MOLECULAR FORMULA: C₂₂H₂₇N₅O₄

5

MOLECULAR WEIGHT: 425.48

CAS NUMBER: 1013101-36-4

APPEARANCE: Crystalline solid

SOLUBILITY: DMSO (>10 mg/ml)

PURITY: ≥98% by HPLC

STORAGE: At -20° C. Protect from light and moisture

DESCRIPTION: A potent, ATP-competitive PI3K/mTOR dual inhibitor with broad antitumor activity. PF-04691502 potently inhibits recombinant class I PI3K and mTOR in biochemical assays and suppresses transformation of avian fibroblasts mediated by wild-type PI3K γ , δ , or mutant PI3K α .

REFERENCE: Yuan, J., *et al.* (2011). *Mol. Cancer Ther.* **10**, 2189-2199.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

RELATED PRODUCTS:

BEZ235 (NVP-BEZ235) (Cat. No. 1626-5, 25)
 BI-D1870 (Cat. No. 1824-1, 5)
 Deforolimus (Cat. No. 1587-5, 25)
 DiscoveryPak™ PI 3-Kinase Inhibitor Panel (Cat. No. K856-5)
 Everolimus (Cat. No. 1917-5, 25)
 GDC-0941 (Cat. No. 1623-1,5)
 GSK-2126458 (Cat. No. 1961-1, 5)
 IC87114 (Cat. No. 1661-1)
 LY 294002 (Cat. No. 1667-5, 25)
 mTOR Inhibitor, Ku-0063794 (Cat. No. 1779-1,5)
 mTOR Inhibitor, WYE-28 (Cat. No. 2255-500, 1000)
 mTOR Inhibitor, WYE-132 (Cat. No. 2256-500, 1000)
 mTOR Inhibitor, WYE-23 (Cat. No. 2257-500, 1000)
 PI-103 (Cat. No. 1728-1,5)
 PI3-K γ Inhibitor, AS-605240 (Cat. No. 1780-1,5)
 PathwayReady™ PI3-K/Akt/mTOR Signaling Inhibitor panel (Cat. No. K857-11)
 PP242 (Cat. No. 1658-1)
 PX-866 (Cat. No. 1965-1,5)
 Rapamycin (Cat. No. 1568-5, 50)
 EZSolution™ Rapamycin (Cat. No. 1746-5)
 Temsirolimus (Cat. No. 1600-5, 25)
 TGX-115 (Cat. No. 1660-1)
 TGX-221 (Cat. No. 1781-1,5)
 Torin 1 (Cat. No. 2273-5, 25)
 Torin 2 (Cat. No. 2274-5, 25)
 Wortmannin (Cat. No. 1670)

USAGE: **FOR RESEARCH CH USE ONLY! Not to be used in humans**